Drug intelligence / Profile preview

2',3'-dideoxycytidine-5'-monophosphate

Development stage
Unknown
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01

Overview

**2',3'-Dideoxycytidine‐5'‐monophosphate (ddCMP)** is a synthetic nucleoside analog belonging to the class of pyrimidones. Structurally derived from cytidine by removal of the hydroxyl groups at the 2' and 3' positions and phosphorylation at the 5' position, ddCMP acts as an antiviral agent primarily studied for its activity against retroviruses such as HIV. Its mechanism involves incorporation into viral DNA or RNA by viral polymerases; once incorporated, it functions as a chain terminator due to its lack of a necessary hydroxyl group for further elongation. This halts viral genome synthesis and inhibits replication[1][2][3]. It is considered experimental and not approved for clinical use.

Other names
[(2S,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)oxolan-2-yl]methoxyphosphonic acidpyrimidine 2'-deoxyribonucleoside 5'-monophosphatedeoxycytidine phosphatecytidine 5′-(trihydrogen monophosphate), 2′,3′‐dideoxy-
02

Targets

Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on 2',3'-dideoxycytidine-5'-monophosphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2',3'-dideoxycytidine-5'-monophosphate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call